Blenrep Improves Survival in Multiple Myeloma Trial
The DREAMM-7 phase III trial demonstrated that Blenrep (belantamab mafodotin) combined with bortezomib and dexamethasone significantly reduced the risk of death compared to daratumumab plus bortezomib. The trial met its key secondary endpoint of overall survival in patients with relapsed/refractory multiple myeloma. Safety data will be presented at the 2024 ASH Annual Meeting.
- #general surgery
- #pharmacology
- #general medicine
- #psych
- #rheumatology
- #pathology
- #radiology
- #anaesthesia
- #psychiatry
- #fmt
- #emergency medicine
- #academics
- #nursing
- #pharmacy
- #trichology
- #andrology
- #orthopaedics
- #critical care
- #dermatology
- #dentistry
- #oncology
- #business
- #gastroenterology
- #nephrology
- #diagnostics
- #urology
- #ophthalmology
- #gynaecology - ivf
- #pediatrics
- #neurology
- #ent
- #pulmonology
- #family health
- #cardiology
- #endo-diabetology